GMAB News and Press, Genmab A/S From 05/11/22

Genmab A/S (GMAB) Q1 2022 Earning Conference Call May 11, 2022 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Conference Call Participants Peter Virgil - Citigroup James Gordon - JPMorgan Wimal Kapadia - Bern...

Genmab A/S press release (GMAB): Q1 Operating Profit of DKK 514M. Revenue of DKK 2.12B. FY22 revenue guidance in the range of DKK 11B-12B. Operating profit guidance in the range of DKK 3.2B-4.8B. For further details see: Genmab Q1 Operating Profit of DKK 514M, Revenue of DKK 2.12B

Genmab A/S (GMAB) is scheduled to announce Q1 earnings results on Wednesday, May 11th, before market open. The consensus EPS Estimate is $0.19 (-98.9% Y/Y) and the consensus Revenue Estimate is $294.12M (-81.4% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions ...

The overall price growth since the inception of IDNA is quite impressive, considering the huge impact of the Covid-19 pandemic in the U.S. equity market. Huge price loss in the past 12 months, but positive price gain in the past three years, is an apparently visible trend in Genomics-...

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) PR Newswire - Based on topline results from the EPCORE™ NHL-1 clinical trial, AbbVie and Ge...

Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next steps Data from the clinical trial to be presented at a future medical meeting Large B-...

Genmab (GMAB) said an arbitral tribunal has ruled in favor of Johnson & Johnson's (NYSE:JNJ) Janssen Biotech in both matters related to royalty payments under their license agreement related to cancer drug daratumumab. On the first issue, the tribunal determined by maj...

Analysts continue to disbelieve that the Pfizer/BioNTech Comirnaty vaccine can have a future, while reality shows boosters are needed. Pfizer’s earnings from Comirnaty continue to distort the price of Pfizer stock; this will continue. The more difficult issue is to understa...

Genmab (GMAB +5.6%) ADRs are trading higher on Wednesday after UBS upgraded the Danish biotech to Buy from Neutral, arguing that the company’s valuation does not reflect value for its pipeline assets excluding Epcoritamab, an experimental therapy for blood cancer. Based on a sum-of-the...

Seagen had achieved net product sales of $1.4 billion in 2021, which was an annual growth rate of 38%. TIVDAK was approved in September of 2021 for recurrent or metastatic cervical cancer, potential to expand use of the drug for squamous cell carcinoma of the head and neck. PADCEV...